髓鞘少突胶质细胞糖蛋白抗体相关性疾病合并强直性脊柱炎：脱髓鞘与肿瘤坏死因子抑制剂之间的潜在关联。
Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis: Potential association between demyelination and tumor necrosis factor inhibitors.
机构信息
Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Center for Neuromuscular and Neurological Disorders, University of Western Australia, Perth, WA, Australia; Department of Neurology, Sir Charles Gairdner Hospital, Queen Elizabeth II Medical Centre, Perth, WA, Australia; Institute of Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.
出版信息
Mult Scler Relat Disord. 2021 Jun;51:102889. doi: 10.1016/j.msard.2021.102889. Epub 2021 Mar 10.
Myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) is a newly described demyelinating disease. Ankylosing spondylitis (AS) is an inflammatory disease that predominantly affects the axial skeleton. Treatments for AS, such as tumor necrosis factor alpha (TNFα) inhibitors, may induce demyelination. We report the first case of MOGAD coexisting with AS and postulate a potential association with TNFα inhibitors. Further studies are needed to clarify the risk of demyelinating events following anti-TNFα therapy and to elucidate the relationship between MOGAD and AS.
髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）是一种新描述的脱髓鞘疾病。强直性脊柱炎（AS）是一种主要影响中轴骨骼的炎症性疾病。AS 的治疗方法，如肿瘤坏死因子-α（TNFα）抑制剂，可能会引发脱髓鞘。我们报告了首例 MOGAD 与 AS 共存的病例，并推测其与 TNFα 抑制剂可能存在关联。需要进一步的研究来阐明抗 TNFα 治疗后发生脱髓鞘事件的风险，并阐明 MOGAD 与 AS 之间的关系。
Zotero 插件